Clinical trial
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors…
NCT00201734 · Ohio State University Comprehensive Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00201734 |
|---|---|
| Title | Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary |
| Official title | A Phase I Dose Escalation Study of Capecitabine, Carboplatin and Weekly Paclitaxel and a Phase II Trial of the Same Combination in Patients With Adenocarcinoma of Unknown Primary |
| Lead sponsor | Ohio State University Comprehensive Cancer Center, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Tumors, Unknown Primary Tumors, Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Capecitabine, Carboplatin, Paclitaxel |
| Enrollment | 57 |
| Start date | Jun 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Jun 1, 2013 |
| First posted | Sep 20, 2005 |
| Last update posted | Sep 23, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: